HC Wainwright Initiates Buy on Jade Biosciences with $25 Price Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: Benzinga
- Rating Initiation: HC Wainwright & Co. analyst Arthur He initiated coverage on Jade Biosciences Inc (NASDAQ:JBIO) with a Buy rating and a price target of $25, reflecting confidence in the company's future growth potential.
- Market Performance: Jade Biosciences shares closed at $13.17 on Tuesday, and the analyst's target price implies an upside of over 89%, which could attract more investor interest in the stock.
- Industry Outlook: With the ongoing development in the biotech sector, Jade Biosciences' new products and technologies are expected to drive market share growth, and the positive rating may further enhance market confidence in the company.
- Investor Attention: The analyst's Buy rating and high price target could prompt more institutional investors to consider increasing their positions in the stock, thereby enhancing its liquidity and market recognition.
Analyst Views on JBIO
Wall Street analysts forecast JBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JBIO is 23.75 USD with a low forecast of 17.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.020
Low
17.00
Averages
23.75
High
28.00
Current: 17.020
Low
17.00
Averages
23.75
High
28.00
About JBIO
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
